喉癌MTS1/P16基因缺失及异常甲基化的研究  

The Deletion and Aberrant Methylation of MTS1/P16 Gene in Laryngeal Cancer

作　　者：王世瑜[1] 穆红[1] 

机构地区：[1]天津市第一中心医院检验科,300192

出　　处：《天津医药》2008年第4期258-260,共3页Tianjin Medical Journal

摘　　要：目的:研究MTS1/P16基因在人喉癌组织及相应癌旁组织中的变化。方法:采用多重PCR法检测69例患者喉癌组织及相应癌旁组织中MTS1/P16基因的缺失情况;对未检出缺失的标本用甲基化敏感内切酶SmaI消化后再扩增,检测其异常甲基化。结果:在69例患者癌旁组织中未检测到MTS1/P16基因缺失及异常甲基化。69例患者喉癌组织中有17例(24.64%)标本MTS1/P16基因缺失,余52例未检测到MTS1/P16基因缺失的喉癌组织标本有8例(15.38%)检出异常甲基化。结论:MTS1/P16基因变异可能在喉癌的发生、发展中起一定作用。Objective： To investigate the alteration of MTS1/P16 gene in human laryngeal cancer tissue and tumoradjacent tissue speciments. Methods： Homozygous deletion of P16 gene of laryngeal cancer tissue and tumor-adjacent tissue were examined using multiple PCR method in 69 patients with human laryngeal cancer. Samples which had not been found homozygous deletion were digested by restriction endonuclease Sinai for analyzing aberrant DNA methylation. Results： No deletions and abnormal methylation were detected in 69 patients with tumor-adjacent tissue samples. Seventeen patients （24.64%） with laryngeal cancer revealed deletion of P16 gene,and 8 cases （15.38%） of abnormal methylation were detected. Conclusion： MTS1/P16 gene alterations may play a role in the progression of human laryngeal

关 键 词：喉肿瘤 基因 P16 聚合酶链反应 基因缺失 甲基化 

分 类 号：R735.2[医药卫生—肿瘤] R734.202[医药卫生—临床医学]